雄激素受体在早期乳腺癌中的表达及其预后意义

目的探讨雄激素受体(AR)在早期乳腺癌中的表达及其预后意义。方法女性乳腺癌病人159例,采用免疫组织化学检测标本中AR的表达情况,分析AR不同表达状态与雌激素受体、雌激素受体β、孕激素受体、表皮生长因子受体-2、Ki-67表达的联系,并结合病人的年龄、月经状态、组织学分级、淋巴结状态、肿瘤大小、分子分型以及病理分期等临床病理特征观察AR的表达与早期乳腺癌病人的预后相关性。结果乳腺癌组织中AR的表达阳性率为64.8%(103/159)。AR的表达与雌激素受体、孕激素受体、组织学分级、Ki-67和分子分型相关。AR的表达与年龄、月经状态、淋巴结状态、肿瘤大小、病理分期、表皮生长因子受体-2和雌激素受体β等无关。AR在雌激素受体阳性病人中的无病生存率、总体生存率分别为88.7%、97.1%,均较雌激素受体阴性者(75.8%、86.2%)高。AR与雌激素受体阴性病人的无病生存率相关,与雌激素受体阴性者的总生存率无关。结论 AR在乳腺癌中具有较高的表达,AR与雌激素受体的表达状态高度相关。AR对乳腺癌预后影响与雌激素受体表达状态相关。     

三阴性乳腺癌的临床病理特征分析

目的:探讨三阴性乳腺癌(triple negative breast cancer,TNBC)的临床病理特点,以及TNBC中突变型p53的表达及其意义。方法:回顾性分析195例乳腺癌病例,按雌激素受体、孕激素受体、人表皮生长因子受体2的表达分为TNBC组34例和对照组161例。检测TNBC组织中突变型p53的表达,分析其与TNBC临床病理特征及预后的关系。结果:TNBC组病人的复发转移率较高(29.4%比1.2%,P0.001)、无病生存率显著低于对照组(52.9%比90.7%,P0.001)。TNBC组突变型p53阳性表达率明显高于对照组(47.1%比22.4%,P0.01),且突变型p53阳性表达与TNBC腋窝淋巴结转移有关(77.8%比36.0%,P0.05)。结论:TNBC乳腺癌复发转移率高,无病生存率较低,预后较差。TNBC组织中突变型p53表达上调,其可作为TNBC重要的预后指标。     

c-erbB-2和cox-2在乳腺癌中的表达及其意义

应用免疫组化技术 ,检测人乳腺良恶性疾病组织中c erbB 2和cox 2蛋白的表达 ,分析其与淋巴结转移、激素受体状态的关系。 40例乳腺癌组织中c erbB 2表达阳性率为 3 5 .0 %,淋巴结阳性及激素受体阴性者表达率显著高于无淋巴结转移及受体阳性者 (均P <0 .0 5 ) ;cox 2表达阳性率为 47.5 %,激素受体阴性者表达率显著高于受体阳性者 (P <0 .0 5 ) ,但与淋巴结转移无关 (P >0 .0 5 )。 10例良性乳腺疾病及 2例正常乳腺组织中无c erbB 2表达 ,仅有 1例乳腺囊肿病cox 2表达阳性 ,c erbB 2与cox 2的表达存在显著的相关性 (P <0 .0 5 )。提示c erbB 2和cox 2与乳腺癌的发生、转移及预后均有密切关系 ,同时进行两者的免疫组化检测对评估乳腺癌的预后及选择靶向治疗对象可能有意义。     

雄激素受体在三阴性乳腺癌中的表达及预后意义

目的探讨雄激素受体(androgen receptor,AR)在三阴性乳腺癌中的表达情况及其与临床病理特征的关系。方法三阴性乳腺癌病人133例,临床及病理资料完整、无远处转移、未行新辅助化疗。应用免疫组化法检测肿瘤组织中AR的表达情况,分析AR表达与临床病理特征及预后的相关性。结果 133例病人中AR表达阳性38例,阳性率为28.6%。AR阳性与年龄(≥50岁)、绝经状态、较低的Ki-67指数和CK5/6阴性相关(P0.05),与初潮年龄、体质量指数、是否合并糖尿病、是否有恶性肿瘤家族史、组织学分级、淋巴结状态、脉管癌栓、临床分期、EGFR状态等因素无相关性(P0.05)。生存分析显示,AR阳性组病人在总生存上优于AR阴性组,无病生存无差异。结论 AR阳性与部分临床病理特征有一定的相关性,且AR阳性的三阴性乳腺癌病人有更好的总生存,提示AR或许可以成为三阴性乳腺癌新的预后指标或治疗靶点。     

雄激素受体在雌激素受体阳性乳腺癌中的表达及预后意义

目的检测雄激素受体(AR)蛋白在雌激素受体(ER)阳性乳腺癌中的表达情况并探讨其预后意义。方法回顾性分析2012年1月至2012年12月期间在西南医科大学附属医院乳腺外科就诊的ER阳性女性原发性乳腺癌患者的临床病理资料。采用免疫组织化学方法检测乳腺癌组织中AR蛋白表达情况,同时分析AR蛋白表达与患者的年龄、肿瘤直径、侵袭性生物学行为、分子分型等临床病理特征及术后生存情况的关系。结果 130例ER阳性乳腺癌患者中AR蛋白阳性表达76例(58.5%)。低分化、临床分期Ⅲ+Ⅳ期、p53阳性、有神经脉管侵犯及有淋巴结转移患者中AR蛋白表达阳性率均分别明显低于中分化及高分化、临床分期Ⅰ+Ⅱ期、p53阴性、无神经脉管侵犯及无淋巴结转移患者(P0.050),而AR蛋白表达阳性率与患者的年龄、月经状态、肿瘤直径、孕激素受体和Her-2状态、Ki-67及分子分型均无关(P0.050)。AR蛋白阳性表达患者的3年和5年总生存情况和无瘤生存情况均明显优于AR蛋白阴性表达患者(P0.050)。AR蛋白阳性表达患者的5年累积总生存率及无瘤生存率均明显优于AR蛋白阴性表达患者(χ~2=8.134,P=0.004;χ~2=9.150,P=0.002)。结论 ER阳性乳腺癌中AR蛋白阳性表达的患者具有更好的肿瘤分化、更低的临床分期及更弱的肿瘤侵袭性,经规范化治疗后患者的远期生存也优于AR蛋白阴性表达者,提示AR有可能成为治疗ER阳性乳腺癌的一个潜在的新靶点。     

前列腺癌组织中性激素受体表达的分析

目的:定性分析雄激素受体(AR)、雌激素受体(ER)、孕激素受体(PR)在良性前列腺增生(BPH)和前列腺癌(PCa)组织中的阳性表达,为激素治疗PCa和预后判断提供一定的依据。方法:采用免疫组化DAKO Envision二步法,分析30例BPH与32例PCa标本中AR、ER、PR的阳性表达情况。结果:AR、ER、PR阳性数BPH组分别为22、10、6例;PCa组分别为18、14、2例,两组差异无显著性。随访30例PCa患者术后的生存期表明:AR表达阳性者平均生存时间为6.41年,AR阴性者为4.28年,两者差异有统计学意义(P<0.05)。结论:BPH和PCa患者在性激素受体表达上的差异无显著意义;PCa患者中AR表达阳性者平均生存时间长于AR阴性者,后者的预后较差,对AR阴性者行激素治疗效果不确定。     

1560例不同HER2表达状态乳腺癌患者的临床病理特征及预后比较

目的 探讨人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)高表达、低表达及阴性乳腺癌患者的临床病理特征差异和预后差异。方法 回顾性收集2010年1月8日至2015年12月31日期间在武汉大学人民医院乳腺甲状腺外科行手术治疗的女性乳腺癌患者1 560例，根据HER2表达情况分为高表达组、低表达组及HER2阴性组，比较3组乳腺癌患者的临床病理特征差异，并探索预后的影响因素。结果 高表达组乳腺癌患者的组织学分级Ⅲ级、肿瘤>2 cm、淋巴结转移、TNMⅢ期、Ki67高表达、激素受体阴性的比例均高于低表达组和阴性组（P<0.050）；低表达组患者的组织学分级Ⅲ级、肿瘤>2 cm、淋巴结转移和TNMⅢ期比例均高于阴性组（P<0.050），然而Ki67高表达和激素受体阴性表达的比例却低于阴性组（P<0.050）。所有患者均获访，随访时间7～60个月，中位随访时间为60个月，高表达组、低表达组及阴性组乳腺癌患者的5年无病生存率分别为85.6%、80.3%和74.5%,5年总生存率分别为90.4%、86.0%...     

雌激素诱导蛋白及其影响因素在乳腺癌组织中的表达与临床意义

目的：探讨雌激素诱导蛋白（PS2）在乳腺癌中的表达及与其影响因素的关系.方法：应用免疫组织化学SP法检测PS2及其影响因素、ER、PR、c-erbB2在52例乳腺癌中的表达.结果：PS2在乳腺癌中的表达率为59.6%（31/52）.PS2阳性表达与月经状况、ER、PR相关,与肿瘤大小、临床分期、淋巴结状况无关;PS2阳性表达者较阴性表达者5年生存率高,复发率低.结论：PS2可作为预测乳腺癌患者预后的一个独立因子,对乳腺癌患者的抗雌激素治疗有一定指导意义.     

TGF-β RII与HER-2阴性乳腺癌患者预后的关系研究

目的:探讨转化生长因子β1II型受体(TGF-β RII)在人表皮生长因子受体2(HER-2)阴性乳腺癌中的表达变化及与患者预后的关系。方法:收集73例HER-2阴性乳腺癌组织标本(乳腺癌组)、40例正常乳腺组织(正常组)、40例乳腺纤维瘤术后病理组织(纤维瘤)组,采用免疫组化SP法检测3组标本中TGF-β RII的表达情况,并分析其与患者预后的关系。结果:乳腺癌组的TGF-β RII阳性表达率(24.66%)显著的低于纤维瘤组(70.00%)和正常组的(82.50%)且差异具有统计学意义(P0.05);乳腺癌组织中的TGF-β RII阳性表达与患者的TNM分期、发生淋巴结转移、组织学分级有关(P0.05)。Cox分析显示:乳腺癌组织患者TGF-β RII阳性表达是患者远期预后的保护因素(OR=0.644,P0.05);患者的TNM分期、发生淋巴结转移、组织学分级是患者远期预后的危险因素(OR=1.338,OR=1.276,OR=1.552,均P0.05)。结论:TGF-β RII在HER-2阴性乳腺癌中表达下调可能与疾病的发生发展及不良预后具有一定的关系。     

雌、孕激素受体和Her-2阴性乳腺癌的临床病理特征

目的 评价雌、孕激素受体和Her-2表达均阴性乳腺癌(triple-negative breast cancer,TNBC)的临床病理特征及其对预后的影响.方法 500例乳腺癌采用免疫组化筛选TNBC,观察TNBC的临床病理特征,并对其中243例乳腺癌进行临床随访. 结果 500例乳腺癌中TNBC占17.6%(88/500).组织学类型主要为浸润性导管癌(NOS)、化生性癌和髓样癌.组织分级Ⅲ级占72.7%(64/88),高于激素受体阳性组和Her-2高表达组(P=0.000).TNBC中CK5/6阳性率30.7%(27/88),EGFR阳性率34.1%(30/88).TNBC中ERCC1和KIT阳性率分别为28.4%(25/88)和34.1%(30/88),均分别高于激素受体阳性组和Her-2高表达组(P=0.032和P=0.026).TNBC 3年累积生存率为71.5%,低于激素受体阳性组(P=0.021),与Her-2高表达组差异无统计学意义(P=0.474). 结论 TNBC是一类具有高侵袭性病理特征和预后不良的乳腺癌;部分病例表达EGFR和ERCC1.     

Does Androgen Receptor Have a Prognostic Role in Patients with Estrogen/Progesterone-Negative and c-erbB-2-Positive Breast Cancer?

Recently, it has been shown that androgen and androgen receptor (AR) also have an important role in the pathogenesis and outcome of breast cancer. However, their significance in different subtypes of breast cancer is still under investigation. The aim of this study was to study the effects of AR on clinicopathological features and prognosis in patients with estrogen and progesterone receptor (ER/PR)-negative, HER2-positive breast cancer. Tumor paraffin-embedded blocks from archives were used for AR study. Data of patients with ER/PR-negative and HER2-positive breast cancer diagnosed at our institute between 1999 and 2010 were recorded and analyzed retrospectively. We studied 36 patients with ER/PR-negative and HER2-positive breast cancer for AR status. Sixteen of them (44.4%) showed AR positivity. The median age was 47 and 56 years for AR-negative and -positive patients, respectively (P = 0.03). The number of postmenopausal patients was higher in the AR-positive than -negative group (56 vs 30%) (P = 0.01). Other demographic data were similar in both group. Histopathological parameters and tumor and nodal stages were similar in both groups. Trastuzumab treatment was more frequently given to AR-positive than -negative patients (94 vs 44%) (P = 0.01). Median follow-up was 47.1 and 34.7 months in AR-negative and -positive groups, respectively (P = 0.03). Relapse occurred in six and four patients in AR-negative and -positive groups. Median progression-free survival (PFS) was similar in both groups (15.7 and 19.6 months in AR-negative and -positive patients, respectively; P = 0.56). Two patients died at 23.4 and 46 months of follow-up in the AR-negative group. There were no deaths in the AR-positive group. Overall survival analyses were not done as a result of an unmet number of events. Median PFS was similar in AR-positive and -negative in that group of patients with ER/PR-negative and HER2-positive breast cancer. However AR-positive patients were more frequently postmenopausal, older, and positive for lymphovascular space invasion. More frequently applied trastuzumab in the AR-positive group might have an effect on the similarity of PFS between the two groups. Studies with higher numbers in this subset of patients with breast cancer will give more robust data.     

Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells

BACKGROUND: The A Disintegrin And Metalloprotease (ADAM) family is a group of transmembrane proteins containing cell adhesive and proteolytic functional domains. ADAM9 expression was shown to be mediated by androgen receptor (AR) and stress conditions. This study determined a common mediator responsible for ADAM9 protein regulation which supports human prostate cancer (PCa) cell growth and survival. METHODS: ADAM9 protein expression was measured under androgen, anti-androgen, hydrogen peroxide, and/or serum starvation conditions in PCa cells. The roles of reactive oxygen species (ROS) were assessed in the presence or absence of recombinant catalase, or in cells stably transfected with either catalase- or a control neo-cDNA expression vector. ROS was assayed by dihydroethidium (DHE) followed by FACS analysis. RESULTS: ADAM9 protein expression was upregulated by androgen in AR-positive but not in AR-negative PCa cells. The anti-androgen bicalutamide effectively blocked this induction. While serum starvation enhanced ADAM9 expression in AR-positive PCa cells, this stress condition did not alter ADAM9 expression in AR-negative PCa cells. Parallel results also showed that androgen treatment or serum starvation enhanced ROS only in AR-positive but not in AR-negative PCa cells. ROS appears to be a common downstream mediator of androgen- or serum starvation-induced ADAM9 expression since addition of hydrogen peroxide or introduction of catalase, either enhanced or abolished respectively ADAM9 protein expression by both AR-positive and -negative PCa cells. CONCLUSIONS: These findings suggest that ROS is: a common mediator responsible for ADAM9 protein induction in human PCa cells, downstream from AR, and stress response signaling.     

表皮生长因子受体和蛋白激酶B在胃癌组织中的表达及临床意义

目的探讨胃癌组织表皮生长因子受体（EGFR）和蛋白激酶B（AKT）在胃癌组织中的表达与胃癌临床病理特征及预后的关系。方法采用免疫组织化学方法检测84例胃癌组织和15例非癌胃组织中EGFR和AKT的表达情况,并分析其表达与胃癌患者临床病理特征及预后的关系。结果EGFR和AKT在胃癌组织的阳性表达率分别为55．9％（47／84）和64．3％（54／84）,明显高于非癌胃组织的20．0％（3／15）和6．7％（1／15）,差异均有统计学意义（P〈0．05,P〈0．01）。EGFR表达与胃癌分期有关,AKT表达则与胃癌淋巴结转移有关（均P〈0．01）。EGFR阴性表达和阳性表达患者5年总体生存率分别为49％和22％（P〈0．05）;AKT阴性表达和阳性表达患者5年总体生存率分别为45．7和30．2％（P〈0．05）。结论检测胃癌组织中的EGFR和AKT的表达,有助于判断胃癌恶性程度及评估预后。     

CD44+/CD24-/low在乳腺癌中表达及其临床意义

目的 观察乳腺癌中CD44+/CD24-/low的表达与临床病理特征的关系及其对预后的影响.方法 应用双染免疫组织化学检测144例乳腺癌与30例乳腺良性肿瘤或正常乳腺组织中CD44+/CD24-/low的表达,收集并分析患者的临床病理和随访资料.结果 CD44+/CD24-/low在乳腺良性肿瘤或正常乳腺中表达率为0%～8%,乳腺癌中表达率为0%～75%.67例(46.5%)乳腺癌患者CD44+/CD24-/low表型的细胞>10%,余77例(53.5%)≤10%.CD44+/CD24-/low的表达高低在淋巴结转移(P<0.01)、病理分期(P<0.01)、HER-2表达(P<0.01)以及复发(P<0.01)上差异有统计学意义.CD44+/CD24-/low高表达的肿瘤复发时主要表现为远处转移,尤其是骨转移.CD44+/CD24-/low高表达和低表达的5年无病生存率为65%和82%(P<0.01),5年总生存率为68%和86%(P<0.05),差异有统计学意义.结论 CD44+/CD24-/low的表达可能与乳腺癌的转移有关,有可能作为评估乳腺癌患者预后的参考指标.     

Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy

PURPOSE: We compared and evaluated clinical outcomes in patients with pathological superficial (pT2a) and deep (pT2b) invasion of bladder muscle with transitional cell carcinoma following radical cystectomy and urinary diversion. MATERIALS AND METHODS: From 1971 to 2001, 311 of 1,359 patients (23%), including 244 males (78%) and 67 females, were found to have pathological muscle invasive (pT2) bladder cancer following radical cystectomy. Of this group 147 patients (47%) had pT2a (superficial) and 164 (53%) had pT2b (deep) muscle invasive tumors. Overall 242 patients had no evidence of lymph node metastasis, including 127 with pT2a (86%) and 115 with pT2b (70%). A total of 69 patients (22%) had lymph node involvement, including 20 with pT2a (14%) and 49 with pT2b (30%). At a median followup of 14.3 years (range 0 to 30.1) clinical outcomes were determined, including recurrence-free and overall survival, and local vs distant recurrence. RESULTS: In the 311 patients with pT2 tumors 10-year recurrence-free and overall survival rates were 72% and 47%, respectively. There was a significantly higher risk of node positive disease with pT2b vs pT2a tumors (30% vs 14%, p <0.001). No significant difference was observed in 10-year recurrence-free survival in patients with pT2a node negative vs pT2b node negative tumors (84% vs 72%, p = 0.091). When comparing pT2a node positive vs pT2b node positive tumors, no significant difference was observed in 10-year recurrence-free survival (50% vs 48%, p = 0.84). Recurrence-free survival was significantly higher in patients with pT2 lymph node negative tumors than in those with pT2 lymph node positive tumors (79% vs 49%, p <0.001). Furthermore, these differences remained significant when stratified by pT2a and pT2b node negative vs positive disease. Local pelvic recurrence developed in 10 of 311 patients (3%) with pT2 disease, while 69 (22%) had distant metastatic disease. In patients with recurrence the local or distant recurrence site was not associated with tumor stage (pT2a vs pT2b p = 0.24) or lymph node status (node negative vs positive p = 0.37). CONCLUSIONS: In muscle invasive (pT2) bladder cancer treated with radical cystectomy there is a higher risk of lymph node positive disease in deep muscle (pT2b) vs superficial (pT2a) invasion. However, no apparent difference was observed in recurrence-free survival between pT2a (superficial) vs pT2b (deep) muscle invasive tumors when controlling for lymph node status. Recurrence-free survival is significantly improved in patients with pT2 lymph node negative tumors compared to survival in those with pT2 lymph node positive tumors. Patients with muscle invasive (pT2), lymph node negative tumors have excellent clinical outcomes following cystectomy, while those with muscle invasive (pT2), lymph node positive tumors have higher recurrence rates and should be considered for adjuvant treatment protocols.     

脂肪酸合成酶在三阴性乳腺癌中的表达及其预后价值

目的探讨脂肪酸合成酶（fatty acid synthase,FAS）在三阴性乳腺癌（triple-negative breast cancer,TNBC）中的表达及其预后价值。方法回顾性分析安徽省滁州市第一人民医院及江苏省肿瘤医院2006年1月至2012年12月手术病理确诊的TNBC176例的免疫组化检测FAS的表达情况,统计学分析FAS的不同表达情况与临床病理特征及预后的相关性。结果 TNBC中FAS的阳性率为68%。FAS与肿瘤大小、组织学分级、淋巴结转移有相关性。随访显示,FAS阳性者的5年总生存率和无病生存率均低于FAS阴性者（55% vs.84%,21% vs.73%,均P〈0.01）。结论 TNBC中FAS阳性者预后差,FAS可能成为TNBC新的治疗靶点及预后指标。     

ER和PR及HER-2表达与乳腺癌分子分型及临床特征和预后的关系

目的:利用雌激素受体(ER)、孕激素受体(PR)及人表皮生长因子受体2(HER-2)的免疫组织化学检测结果将乳腺癌简易分为4种分子亚型,并探讨这4种分子亚型的临床特征和影响预后的相关因素。方法:根据ER、PR及HER-2的免疫组织化学检测结果,采用回顾性方法将本院收治的175例乳腺癌患者简易分为类luminal A型、类luminal B型、类HER-2(+)型及类basal-like型4种类型。对各型的临床特征采用SPSS17.0统计软件进行分析,并用Kaplan-Meier法和Cox回归分析各型乳腺癌患者的生存情况及预后因素。结果:在175例乳腺癌患者中,类luminal A型、类luminal B型、类HER-2(+)型及类basal-like型分别占56.00%(98/175)、17.71%(31/175)、12.57%(22/175)和13.71%(24/175)。类basal-like型与类luminal A型相比,患者无瘤生存率较低(P0.05)。经Cox多因素预后分析,淋巴结阳性患者的预后较淋巴结阴性患者差;类luminal A型患者预后最好,而类basal-like型患者预后最差。结论:淋巴结状况及分子分型是影响乳腺癌预后的重要因素。依据ER、PR及HER-2行乳腺癌分子分型与国际公认分型的临床表现及预后基本一致,对指导基层医院的乳腺癌预后及治疗同样具有重要意义。     

三阴性乳腺癌和非三阴性乳腺癌临床特征的比较

目的 比较三阴性和非三阴性乳腺癌的临床特征,丰富三阴性乳腺癌的防治资料,为乳腺癌的个体化综合治疗寻找理论依据.方法 回顾性分析2002年收治的乳腺癌患者病例,选择接受手术治疗、资料完整并经免疫组织化学方法明确判定受体状况的408例患者进行分析.通过与非三阴性乳腺癌的比较,分析三阴性乳腺癌的临床特征、复发及生存情况.结果 本组资料中确认三阴性乳腺癌77例,占乳腺癌患者的18.9%(77/408).所有患者中位随访64个月(3～79个月).408例病例中,复发或转移58例,死亡51例,三阴性乳腺癌中复发或转移19例,死亡12例.三阴性乳腺癌患者的年龄较轻,肿瘤体积较大,局部复发率和远处转移率均显著性高于非三阴性乳腺癌患者(P均<0.05).生存分析显示,三阴性乳腺癌患者的3年和5年总生存率(86.4%和77.7%)均显著低于非三阴性乳腺癌患者(93.4%和87.9%)(P均<0.05);三阴性乳腺癌患者的3年和5年无病生存率(78.4%和72.8%)均显著低于非三阴性乳腺癌患者(92.4%和85.8%)(P均<0.05).结论 三阴性乳腺癌具有特定的临床特征,预后比非三阴性乳腺癌差,需要进一步开展三阴性乳腺癌的个体化治疗的研究.     

REG1A Expression is an Independent Factor Predictive of Poor Prognosis in Patients with Breast Cancer

Background  Regenerating gene I alpha (REG1A) is a growth factor known to affect pancreatic islet β cells. Although REG1A expression has also been observed in various malignant tumors, the correlation between REG1A expression and the clinicopathological characteristics of breast cancer and patient prognosis has not been evaluated. Methods  Resected breast cancer tissues obtained at surgery from 150 breast cancer patients was stained with anti-REG1A antibody, after which the relative area occupied by stained tumor cells was evaluated under a light microscope and correlated with known clinicopathological factors. Results  Whereas tumor cells were frequently stained with anti-REG1A antibody, cells from normal breast tissue were not stained. REG1A expression in tumors of breast cancer patients with HER2-positive disease was higher than those with HER2-negative disease (P = .0009). The 10-year disease-specific survival rate among patients with lower levels of REG1A was significantly better than among those with higher levels (P = .0002 by log rank test). Multivariate Cox proportional hazard analyses revealed REG1A (hazard ratio, 2.07; 95% confidence interval, 1.93 to 11.29; P = .0005) and axillary lymph node status (hazard ratio, 4.44; 95% confidence interval, 1.52 to 11.29; P = .0003) to be independent factors affecting the 10-year disease-specific survival rate. Conclusion  High levels of REG1A expression within tumors are an independent predictor of poor prognosis in patients with breast cancer.     

长链非编码RNA-CECR7在胃癌中的表达及预后价值

目的探究长链非编码RNA（lncRNA）-CECR7在胃癌不同组织中的表达情况及其预后价值。 方法以2015年5月至2016年5月成都医学院第一附属医院收治的78例胃癌患者为研究对象，采用实时荧光定量PCR（RT-PCR）方法检测胃癌组织、癌旁组织中lncRNA-CECR7相对表达情况。分析lncRNA-CECR7表达与患者临床病理特征的关系，绘制Kaplan-Meier曲线进行生存分析，Cox回归分析影响患者3年生存率的因素。 结果胃癌组织中的lncRNA-CECR7相对表达量为1.87±0.25，显著高于癌旁组织的1.05±0.13，差异有统计学意义（t=25.701，P<0.001）。lncRNA-CECR7表达与肿瘤大小、Borrmann分型、TNM分期、分化类型、淋巴结转移有关（P<0.05）。患者3年生存率为62.82%（49/78），lncRNA-CECR7低表达组生存率显著高于高表达组（77.14% vs 51.16%，χ²=5.576，P=0.018）。肿瘤大小、TNM分期、淋巴结转移、lncRNA-CECR7表达水平是影响胃癌患者预后的独立因素（P<0.05）。 结论lncRNA-CECR7在胃癌组织中的高表达与肿瘤大小、Borrmann分型、TNM分期有关，是影响胃癌患者3年生存的危险因素。